DIA/FDA Conference on Biosimilars

September 17, 2012

On September 13, Dr. Dolinar presented on two panels at the DIA/FDA Biosimilars Conference: Guidances, Science, and BsUFA in Washington, D.C. His first panel was on Pharmacovigilance, Naming, and Labeling and the second panel was on Interchangeability. DIA Presentation on Biosimilar Naming DIA Presentation on Interchangeability During the conference, ASBM released a new survey examining […]

Read More

ASBM Presents in Toronto, Canada

June 28, 2012

On June 4, Alliance Chairman Dr. Richard Dolinar and Executive Director Michael Reilly presented at the Canadian Patient Experts in Health Technology forum in Toronto, Canada. The forum was organized by Durhane Wong-Rieger, president of the Canadian Organization for Rare Disorders. The two-day event was set up to establish a global network of individual patient […]

Read More

Alliance for Safe Biologic Medicines – Capitol Hill Biosimilars Forum, Washington, D.C.

April 18, 2012

On February 27, 2012, the Alliance for Safe Biologic Medicines and Bloomberg Government hosted a lunch time Biosimilars Forum on Capitol Hill to discuss the FDA’s draft guidance documents on biosimilar product development.

Read More

Alliance’s Dolinar Headlines Boston Biosimilars Event

October 5, 2011

By Kathy Feegal Dr. Richard Dolinar, the Alliance’s chairman, was a keynote speaker at a biosimilars roundtable discussion in Boston, MA on October 5, 2011. The event was hosted by Northeastern University and was attended by numerous stakeholders from across New England, including the Massachusetts Medical Society, and patients groups such as the National Kidney […]

Read More

Biologics and Biosimilars: What Patients, Physicians and Advocates Need to Know Access, Patient Safety and Emerging Policy Issues

September 28, 2011

The Alliance for Safe Biologic Medicines joined with the Virginia Biotechnology Association at an event to expore with patients, advocates, physicians and other healthcare providers the importance of maintaining patient safety as the U.S. FDA’s top priority while it works to establish a pathway for approval for biosimilar products.

Read More

Biosimilars Policy Forum

August 17, 2011

The Alliance for Safe Biologic Medicines and Pennsylvania Bio hosted an event entitled, “Biosimilars Policy Forum: Ensuring Patient Safety” in Philadelphia, PA, on August 17, 2011 The purpose of the forum discussion was to explore with community members, including policymakers, patients, physicians, pharmacists, and hospital officials the importance of maintaining patient safety as the U.S. […]

Read More